Literature DB >> 2127037

Development of a sensitive and rapid chromogenic factor IX assay for clinical use.

R Wagenvoord1, H Hendrix, T Tran, H C Hemker.   

Abstract

A chromogenic factor IX assay is developed which requires only two time-dependent steps. Diluted plasma is mixed with a reagent containing factors VIII and X. The reaction is started by addition of a reagent containing factor XIa, thrombin, CaCl2, and phospholipids. Then factor XIa activates factor IX if present, thrombin activates factor VIII, and subsequently the complete factor X activating complex (factor IXa, factor VIIIa, Ca ions, and phospholipids) rapidly activates factor X. Finally, ethylenediaminetetraacetic acid plus a chromogenic substrate are added to stop the reaction and to measure formed factor Xa. Factor Xa formation is proportional to the plasma factor IX concentration (from 0 to 140%). The two reagents needed for the assay are stable at room temperature during a whole working day and for 3 h at 37 degrees C. A new isolation procedure for factor VIII is described. Factor VIII is purified from bovine plasma in a few steps with a yield of 20% and a 8,000-fold purification.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2127037     DOI: 10.1159/000216139

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  6 in total

1.  Productive recognition of factor IX by factor XIa exosites requires disulfide linkage between heavy and light chains of factor XIa.

Authors:  Mariola M Marcinkiewicz; Dipali Sinha; Peter N Walsh
Journal:  J Biol Chem       Date:  2011-12-29       Impact factor: 5.157

Review 2.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs.

Authors:  T C Nichols; H W G Franck; C T Franck; N De Friess; R A Raymer; E P Merricks
Journal:  J Thromb Haemost       Date:  2012-03       Impact factor: 5.824

4.  Molecular cloning and biochemical characterization of rabbit factor XI.

Authors:  Dipali Sinha; Mariola Marcinkiewicz; David Gailani; Peter N Walsh
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

5.  Epitope reactions can be gauged by relative antibody discriminating specificity (RADS) values supported by deletion, substitution and cysteine bridge formation analyses: potential uses in pathogenesis studies.

Authors:  Andrew K I Falconar
Journal:  BMC Res Notes       Date:  2012-07-05

6.  Development of Methods for the Selective Measurement of the Single Amino Acid Exchange Variant Coagulation Factor IX Padua.

Authors:  Alfred Weber; Andrea Engelmaier; Dirk Voelkel; Robert Pachlinger; Friedrich Scheiflinger; Paul E Monahan; Hanspeter Rottensteiner
Journal:  Mol Ther Methods Clin Dev       Date:  2018-06-28       Impact factor: 6.698

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.